Brief: Oncternal Therapeutics Updates The Status Of Its Phase 1/2 Study Of Onct-808
26/12/2023 14:02
Dec 26 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS UPDATES THE STATUS OF ITS PHASE 1/2
STUDY
OF ONCT-808, A ROR1-TARGETING AUTOLOGOUS CAR T, IN PATIENTS WITH
RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA
* ONCTERNAL THERAPEUTICS INC: HAS BEEN IN COMMUNICATION AND
IS
ALIGNED WITH FOOD AND DRUG ADMINISTRATION (FDA) ON OUR PROPOSED
PROTOCOL CHANGES IN STUDY
Source text for Eikon: ID:nGNX3tvBs5
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;